 The study assessed the safety and immunogenicity of MENACYWTT, a cordivalent meningococcal conjugate vaccine, compared to MPSV4, a cordivalent meningococcal polysaccharide vaccine in 301 healthy adults aged greater than or equal to 56Y. The study found that both vaccines were well tolerated and immunogenic, with higher proportions of participants having HSBA titers greater than or equal to 1,8 against serogroups W and Y after MENACYWTT vaccination compared to MPSV4. This article was authored by Judith Kerstin, Miriam Pena, Judy Pan, and others.